The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
ImmuPharma's stock value has experienced a significant increase of +1.42 (71.00%) in the past 5 days (as of 17 Apr, 16:35 BST). In my personal opinion, the recent RNS announcement presents a compelling case for investment, with numerous strong and positive arguments that are likely to appeal to top investors worldwide. Let's delve into the key reasons behind this upward trajectory:
1. Expanding Pipeline: ImmuPharma's P140 is moving into its second indication for CIDP patients, showcasing the company's ability to diversify and expand its pipeline. The potential to treat a range of indications with the P140 platform, such as autoimmune and inflammatory conditions like lupus and CIDP, highlights the broad potential of ImmuPharma's drug candidates.
2. Addressing Unmet Medical Needs: CIDP is a rare neurological disease with high unmet medical needs. There are limited treatment options for CIDP patients, and ImmuPharma's P140 offers a promising alternative with its unique mechanism of action. By focusing on this underserved patient population, ImmuPharma demonstrates its commitment to innovation and addressing critical healthcare needs.
3. Market Potential: The CIDP market is expected to reach global sales of US$2.7 billion by 2029, providing a lucrative opportunity for ImmuPharma if P140 proves to be successful. A first-in-class treatment for CIDP would give the company a significant competitive advantage and a substantial share of this growing market.
4. Regulatory Progress: ImmuPharma has received confirmation of a pre-IND meeting date with the FDA, marking a critical step in the drug development process. This progress showcases the company's ability to navigate the complex regulatory environment and move its drug candidates closer to commercialization.
5. Orphan Drug Status: If ImmuPharma receives Orphan Drug status for P140 following the pre-IND meeting, the company will benefit from 7 years of market exclusivity post-marketing approval. This exclusivity provides a competitive advantage and the potential for substantial financial returns during that period.
6. Management Expertise: The company's management team, led by CEO Tim McCarthy, has demonstrated a strategic approach to drug development, collaborating with contract research organizations and CIDP opinion leaders from Europe and the USA. This collaboration showcases the company's commitment to leveraging external expertise to develop innovative therapies.
7. Potential for Future Growth: The unique mechanism of action of P140 has been linked to other diseases, suggesting that the platform could be expanded further to treat conditions like asthma, irritable bowel disease, periodontitis, and gout. This potential for future growth offers long-term investment opportunities and value creation.
NOTE: The information provided in this analysis is based on my personal opinion and for informational purposes only and should not be construed as investment advice or a recommendatio
Holding very well at this level, big move up towards 5p coming on FDA date rns imo
" At least Lambo has shares to sell ; ) "
has he ?
I suspect that he is just a CFD Trader .... and plays with short/long contracts
"As usual you give Huge targets yet you will sell out well below those :-) Same pump and dump talk as usual, Ha ha , heard it all before on numerous occasions… you will sell out and deramp then , imo but whatever"
At least Lambo has shares to sell ; )
Frits
I have been gobbling these up since 2p, very pleased to see the upwards re-rating of this share. Personally I will be holding till MCAP hits £25m and then trimming the fat off of this beautiful bird.
Ha ha , heard it all before on numerous occasions… you will sell out and deramp then , imo but whatever..
I would not even consider selling any until 5p is breached, FDA meeting date is imminent which should really get the momentum going here
Lambo222,
As usual you give Huge targets yet you will sell out well below those :-)
Same pump and dump talk as usual
Poker. Well done.
Regards to Nopulus
Not many sellers at this low level, this traded at 7p ahead of last years FDA meeting, as we build up to the meeting over the next few weeks history will repeat imo and the price will head towards 7p yet again, and this time we have the CIDP FDA approval meeting to look forward to on 16th May, also news of Avion collaboration overdue and 5p warrants expiring on 10th June, you can see exactly where the price is going, 3p is long gone
Looks like someone is accumalating down here...
News not far away.
i expect this will finish nearer 3p than 4p by close of play. nice to dream of the 6p / 10p brigade predictions but in reallity we'll more than likely see 30% then a slow drift back down to 3p this afternoon .. imo
supply zone in shaded area to watch for
https://invst.ly/-si2g
MMs using the spread and logging some buys as sells - have a feeling this is about to pop over 4p
better late than never HB'' GL, as i think they will put it out of everyone reach shortly''
Back in
One would have to agree that 5p is a target/milestone for IMM ( even more so , IF they need to raise cash again without giving penalty warrants to the L club again ) imo
I don't suppose there are too many shares available ..hence the quick move up...when they are gone they are gone ... need them all in safe hands now ...stop the silly flipping at these low levels...
The Tims have Options and shares @5p ....plenty of incentive to get things the other side of that ..they are no doubt patient and see the mid-long term outlook of it all....
Just need a few buy's and we are off
Look at the big buying, I can see 4p by 12pm
All imho, dyor
nice to see you bullish LAMB'' that mean we can expect 10p in the not too distant LOL!!
GL
just listen to the chart with ZAK and he gives it 6.5p shortly
we will see
ATB
Perhaps a takeover approach by Avion or a PE - I know some have thrown cold water over the idea, but that is a possibility. Heading to the meeting with the FDA with 2 strings to the bow in what is a multi billion pound sector. Our market cap is £10 million - puts this into the context of how early some investors are getting in
Breaking out higher……best to just add a little at this level - it’s so close top the bottom. Next month could see buyers at 15p+
up 18% and going much higher
This is like a coiled spring I feel there is a buyer mopping them up at this level - The market is aware of the potential upside